A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants with Parkinson’s Disease (PD)

Grant

Date/time Interval

  • January 3, 2018 - January 2, 2022

    • Awarded By

    Total Award Amount

  • 241251.00

    • Direct Costs

  • 193001.00

    • Sponsor Award Id

    • Contributor

  • Amy Amara   Investigator  
  • Natividad Stover   Principal Investigator